Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Introduction Phase 3 trials have shown comparable efficacy of direct oral anticoagulants
(DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE) …

Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of
acute venous thromboembolism. This study sought to evaluate the efficacy and safety of …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Venous thromboembolism (VTE) results in significant morbidity and mortality. The
prevention and treatment of VTE is managed with anticoagulant therapy, historically …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for
patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer …